| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454567 | Lung Cancer | 2016 | 6 Pages |
Abstract
Combining data from our and prior cohorts, ALK kinase domain mutations were uncommon events (<3% of cases) in ALK inhibitor-naïve ALK rearranged lung adenocarcinomas but their effect on intrinsic resistance to ALK inhibitors should be better evaluated.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Antonio R. Lucena-Araujo, Jason P. Moran, Paul A. VanderLaan, Dora Dias-Santagata, Erik Folch, Adnan Majid, Michael S. Kent, Sidharta P. Gangadharan, Deepa Rangachari, Mark S. Huberman, Susumu S. Kobayashi, Daniel B. Costa,